Form 8-K - Current report:
SEC Accession No. 0001171843-24-006034
Filing Date
2024-11-06
Accepted
2024-11-06 07:00:13
Documents
15
Period of Report
2024-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_110624.htm   iXBRL 8-K 15274
2 PRESS RELEASE exh_991.htm EX-99.1 407292
  Complete submission text file 0001171843-24-006034.txt   659451

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
18 EXTRACTED XBRL INSTANCE DOCUMENT f8k_110624_htm.xml XML 3231
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 241429180
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)